Seeking a mechanism for the toxicity of oligomeric α-synuclein

Biomolecules

Volumn 5, Issue 2, 2015, Pages 282-305

  Roberts, Hazel L ^a   Brown, David R ^a  

^a University of Bath   (United Kingdom)

Author keywords

Aggregation; Amyloid fibrils; Neurodegeneration; Parkinson s disease; Toxic oligomers; synuclein

Indexed keywords

CELL DEATH; CELL DISRUPTION; CELL MEMBRANE DEPOLARIZATION; CYTOLYSIS; CYTOSOLIC FRACTION; CYTOTOXICITY; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM STRESS; EXPERIMENTAL MODEL; GEL PERMEATION CHROMATOGRAPHY; GENE EXPRESSION; GENE MUTATION; HUMAN; INFRARED SPECTROSCOPY; MEMBRANE PERMEABILITY; MOLECULAR DYNAMICS; NERVOUS SYSTEM INFLAMMATION; OLIGOMERIZATION; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SOLUBILITY; UNFOLDED PROTEIN RESPONSE; ANIMAL; GENETICS; METABOLISM; MUTATION; PROTEIN MULTIMERIZATION; PROTEINOSIS;

ALPHA SYNUCLEIN; AMYLOID;

ALPHA-SYNUCLEIN; AMYLOID; ANIMALS; HUMANS; MUTATION; NEURODEGENERATIVE DISEASES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN MULTIMERIZATION;

EID: 85012093582     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom5020282     Document Type: Review

References (121)

1. Conway, K.A.; Lee, S.; Rochet, J.; Ding, T.T.; Williamson, R.E.; Lansbury, P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson’s disease: Implications for pathogenesis and therapy. PNAS 2000, 97, 571–576.
2. Kayed, R.; Head, E.; Thompson, J.L.; Mcintire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300, 486–489.
3. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.-Y.; Trojanowski, J.Q. α-Synuclein in Lewy bodies. Nature 1997, 388, 839–840.
4. Irwin, D.J.; Lee, V.M.-Y.; Trojanowski, J.Q. Parkinson’s disease dementia: Convergence of α-synuclein, tau and amyloid-β pathologies. Nat. Rev. Neurosci. 2013, 14, 626–636.
5. Lashuel, H.A.; Overk, C.R.; Oueslati, A.; Masliah, E. The many faces of α-synuclein: From structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 2013, 14, 38–48.
6. Hamilton, R.L. Lewy bodies in Alzheimer’s disease: A neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000, 10, 378–384.
7. Parkkinen, L.; Soininen, H.; Alafuzoff, I. Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J. Neuropathol. Exp. Neurol. 2003, 62, 363–367.
8. Jellinger, K.A. Lewy body-related alpha-synucleinopathy in the aged human brain. J. Neural Transm. 2004, 111, 1219–1235.
9. Larson, M.E.; Sherman, M.A.; Greimel, S.; Kuskowski, M.; Schneider, J.A.; Bennett, D.A.; Lesné, S.E. Soluble α-synuclein is a novel modulator of Alzheimer’s disease pathophysiology. J. Neurosci. 2012, 32, 10253–10266.
10. Chartier-Harlin, M.; Kachergus, J.; Roumier, C.; Mouroux, V.; Douay, X.; Lincoln, S.; Levecque, C.; Larvor, L.; Andrieux, J.; Hulihan, M; et al. α-Synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 2004, 364, 1167–1169.
11. Ahn, T.B.; Kim, S.Y.; Kim, J.Y.; Park, S.S.; Lee, D.S.; Min, H.J.; Kim, Y.K.; Kim, S.E.; Kim, J.M.; Kim, H.J; et al. α-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008, 70, 43–49.
12. Kasten, M.; Klein, C. The many faces of alpha-synuclein mutations. Mov. Disord. 2013, 28, 697–701.
13. Krüger, R.; Kuhn, W.; Müller, T.; Woitalla, D.; Graeber, M.; Kösel, S.; Przuntek, H.; Epplen, J.; Schöls, L.; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 1998, 18, 106–108.
14. Zarranz, J.; Alegre, J.; Gómez-Esteban, J.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atarés, B; et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55, 164–173.
15. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R; et al. Mutation in the α-synuclein gene identified in families with Parkinson’s Disease. Science 1997, 276, 2045–2048.
16. Appel-Cresswell, S.; Vilarino-Guell, C.; Encarnacion, M.; Sherman, H.; Yu, I.; Shah, B.; Weir, D.; Thompson, C.; Szu-Tu, C.; Trinh, J; et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s disease. Mov. Disord. 2013, 28, 811–813.
17. Lesage, S.; Anheim, M.; Letournel, F.; Bousset, L.; Honoré, A.; Rozas, N.; Pieri, L.; Madiona, K.; Dürr, A.; Melki, R; et al. G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 2013, 73, 459–471.
18. Hoffman-Zacharska, D.; Koziorowski, D.; Ross, O.A.; Milewski, M.; Pozna_ski, J.; Jurek, M.; Wszolek, Z.K.; Soto-Ortolaza, A.; Sβawek, J.; Janik, P; et al. Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson’s disease. Parkinsonism Relat. Disord. 2013, 19, 1057–1060.
19. Fredenburg, R.A.; Rospigliosi, C.; Meray, R.K.; Kessler, J.C.; Lashuel, H.A.; Eliezer, D.; Lansbury, P.T.J. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 2007, 46, 7107–7118.
20. Brucale, M.; Sandal, M.; di Maio, S.; Rampioni, A.; Tessari, I.; Tosatto, L.; Bisaglia, M.; Bubacco, L.; Samorì, B. Pathogenic mutations shift the equilibria of alpha-synuclein single molecules towards structured conformers. Chembiochem 2009, 10, 176–183.
21. Li, J.; Uversky, V.N.; Fink, A.L. Effect of familial Parkinson’s Disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry 2001, 40, 11604–11613.
22. Maraganore, D.M.; de Andrade, M.; Elbaz, A.; Farrer, M.J.; Ioannidis, J.P.; Krüger, R.; Rocca, W.A.; Schneider, N.K.; Lesnick, T.G.; Lincoln, S.J; et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson Disease. JAMA 2006, 296, 661–670.
23. Jowaed, A.; Schmitt, I.; Kaut, O.; Wüllner, U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson’s disease patients’ brains. J. Neurosci. 2010, 30, 6355–6359.
24. Olivares, D.; Huang, X.; Branden, L.; Greig, N.H.; Rogers, J.T. Physiological and pathological role of alpha-synuclein in Parkinson’s disease through iron mediated oxidative stress; the role of a putative iron-responsive element. Int. J. Mol. Sci. 2009, 10, 1226–1260.
25. Grosso, H.; Woo, J.M.; Lee, K.W.; Im, J.Y.; Masliah, E.; Junn, E.; Mouradian, M.M. Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast. FASEB J. 2014, 28, 4280–4291.
26. Fauvet, B.; Mbefo, M.K.; Fares, M.-B.; Desobry, C.; Michael, S.; Ardah, M.T.; Tsika, E.; Coune, P.; Prudent, M.; Lion, N; et al. α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 2012, 287, 15345–15364.
27. Breydo, L.; Wu, J.W.; Uversky, V.N. α-synuclein misfolding and Parkinson’s disease. Biochim.Biophys. Acta 2012, 1822, 261–285.
28. Visanji, N.P.; Wislet-Gendebien, S.; Oschipok, L.W.; Zhang, G.; Aubert, I.; Fraser, P.E.; Tandon, A. Effect of Ser-129 phosphorylation on interaction of α-synuclein with synaptic and cellular membranes. J. Biol. Chem. 2011, 286, 35863–35873.
29. Lorenzen, N.; Lemminger, L.; Pedersen, J.N.; Nielsen, S.B.; Otzen, D.E. The N-terminus of α-synuclein is essential for both monomeric and oligomeric interactions with membranes. FEBS Lett. 2014, 588, 497–502.
30. Middleton, E.R.; Rhoades, E. Effects of curvature and composition on α-synuclein binding to lipid vesicles. Biophys. J. 2010, 99, 2279–2288.
31. Bendor, J.T.; Logan, T.P.; Edwards, R.H. The function of α-synuclein. Neuron 2013, 79, 1044–1066.
32. Burré, J.; Sharma, M.; Tsetsenis, T.; Buchman, V.; Etherton, M.R.; Südhof, T.C. α-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329, 1663–1667.
33. Burré, J.; Sharma, M.; Südhof, T.C. α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl. Acad. Sci. USA 2014, 111, 4274–4283.
34. Van Rooijen, B.D.; Claessens, M.M.A.E.; Subramaniam, V. Membrane permeabilization byoligomeric α-synuclein: In search of the mechanism. PLOS ONE 2010, 5, e14292.
35. Ouberai, M.M.; Wang, J.; Swann, M.J.; Galvagnion, C.; Guilliams, T.; Dobson, C.M.; Welland, M.E. α-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling. J. Biol. Chem. 2013, 288, 20883–20895.
36. Wang, C.; Liu, L.; Zhang, L.; Peng, Y.; Zhou, F. Redox reactions of the α-synuclein-Cu2+ complex and their effects on neuronal cell viability. Biochemistry 2011, 49, 323–343.
37. Fellner, L.; Irschick, R.; Schanda, K.; Reindl, M.; Klimaschewski, L.; Poewe, W.; Wenning, G.K.; Stefanova, N. Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia 2013, 61, 349–360.
38. Roodveldt, C.; Labrador-Garrido, A.; Gonzalez-Rey, E.; Fernandez-Montesinos, R.; Caro, M.; Lachaud, C.C.; Waudby, C.A.; Delgado, M.; Dobson, C.M.; Pozo, D. Glial innate immunitygenerated by non-aggregated alpha-synuclein in mouse: Differences between wild-type and Parkinson’s disease-linked mutants. PLOS ONE 2010, 5, e13481.
39. Souza, J.M.; Giasson, B.I.; Chen, Q.; Lee, V.M.; Ischiropoulos, H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 2000, 275, 18344–18349.
40. Krasnoslobodtsev, A.V.; Volkov, I.L.; Asiago, J.M.; Hindupur, J.; Rochet, J.-C.; Lyubchenko, Y.L. Alpha-synuclein misfolding assessed with single molecule AFM force spectroscopy: Effect of pathogenic mutations. Biochemistry 2013, 52, 1–22.
41. Nakamura, K.; Nemani, V.M.; Azarbal, F.; Skibinski, G.; Levy, J.M.; Egami, K.; Munishkina, L.; Zhang, J.; Gardner, B.; Wakabayashi, J; et al. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J. Biol. Chem. 2011, 286, 20710–20726.
42. Bartels, T.; Choi, J.G.; Selkoe, D.J. α-synuclein occurs as a helically folded tetramer that resists aggregation. Nature 2012, 477, 107–110.
43. Dettmer, U.; Newman, A.J.; Luth, E.S.; Bartels, T.; Selkoe, D. In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells. J. Biol. Chem. 2013, 288, 6371–6385.
44. Gould, N.; Mor, D.E.; Lightfoot, R.; Malkus, K.; Giasson, B.; Ischiropoulos, H. Evidence ofnative α-synuclein conformers in the human brain. J. Biol. Chem. 2014, 289, 7929–7934.
45. Kara, E.; Lewis, P.A.; Ling, H.; Proukakis, C.; Houlden, H.; Hardy, J. α-Synuclein mutations cluster around a putative protein loop. Neurosci. Lett. 2013, 546, 67–70.
46. Cremades, N.; Cohen, S.I.A.; Deas, E.; Abramov, A.Y.; Chen, A.Y.; Orte, A.; Sandal, M.; Clarke, R.W.; Dunne, P.; Aprile, F.A; et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 2012, 149, 1048–1059.
47. Lorenzen, N.; Nielsen, S.B.; Buell, A.K.; Kaspersen, J.D.; Arosio, P.; Vad, B.S.; Paslawski, W.; Christiansen, G.; Valnickova-Hansen, Z.; Andreasen, M; et al. The role of stable α-synuclein oligomers in the molecular events underlying amyloid formation. J. Am. Chem. Soc. 2014, 136, 3859–3868.
48. Lashuel, H.A.; Petre, B.M.; Wall, J.; Simon, M.; Nowak, R.J.; Walz, T.; Lansbury, P.T. α-Synuclein, especially the Parkinson’s disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 2002, 322, 1089–1102.
49. Lindersson, E.; Beedholm, R.; Højrup, P.; Moos, T.; Gai, W.; Hendil, K.B.; Jensen, P.H. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 2004, 279, 12924–12934.
50. Bolognesi, B.; Kumita, J.R.; Barros, T.P.; Esbjorner, E.K.; Luheshi, L.M.; Crowther, D.C.; Wilson, M.R.; Dobson, C.M.; Favrin, G.; Yerbury, J.J. ANS binding reveals common features of cytotoxic amyloid species. ACS Chem. Biol. 2010, 5, 735–740.
51. Paleologou, K.E.; Kragh, C.L.; Mann, D.M.A.; Salem, S.A.; Al-Shami, R.; Allsop, D.; Hassan, A.H.; Jensen, P.H.; El-Agnaf, O.M.A. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009, 132, 1093–1101.
52. Van Rooijen, B.D.; Claessens, M.M.A.E.; Subramaniam, V. Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core. Biochim. Biophys. Acta 2009, 1788, 1271–1278.
53. Danzer, K.M.; Haasen, D.; Karow, A.R.; Moussaud, S.; Habeck, M.; Giese, A.; Kretzschmar, H.; Hengerer, B.; Kostka, M. Different species of α-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 2007, 27, 9220–9232.
54. Kostka, M.; Högen, T.; Danzer, K.M.; Levin, J.; Habeck, M.; Wirth, A.; Wagner, R.; Glabe, C.G.; Finger, S.; Heinzelmann, U; et al. Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J. Biol. Chem. 2008, 283, 10992–11003.
55. Choi, B.-K.; Choi, M.-G.; Kim, J.-Y.; Yang, Y.; Lai, Y.; Kweon, D.-H.; Lee, N.K.; Shin, Y.-K. Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. USA 2013, 110, 4087–4092.
56. Zhang, H.; Griggs, A.; Rochet, J.-C.; Stanciu, L.A. In vitro study of α-synuclein protofibrils by cryo-EM suggests a Cu2+-dependent aggregation pathway. Biophys. J. 2013, 104, 2706–2713.
57. Pham, C.L.L.; Cappai, R. The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding. Biosci. Rep. 2013, 33, 807–814.
58. Wright, J.A.; Wang, X.; Brown, D.R. Unique copper-induced oligomers mediate alpha-synuclein toxicity. FASEB J. 2009, 23, 2384–2393.
59. Wang, X.; Moualla, D.; Wright, J.A.; Brown, D.R. Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity. J. Neurochem. 2010, 113, 704–714.
60. Campioni, S.; Mannini, B.; Zampagni, M.; Pensalfini, A.; Parrini, C.; Evangelisti, E.; Relini, A.; Stefani, M.; Dobson, C.M.; Cecchi, C.; et al. A causative link between the structure of aberrant protein oligomers and their toxicity. Nat. Chem. Biol. 2010, 6, 140–147.
61. Zampagni, M.; Cascella, R.; Casamenti, F.; Grossi, C.; Evangelisti, E.; Wright, D.; Becatti, M.; Liguri, G.; Mannini, B.; Campioni, S; et al. A comparison of the biochemical modifications caused by toxic and non-toxic protein oligomers in cells. J. Cell. Mol. Med. 2011, 15, 2106–2116.
62. Olzscha, H.; Schermann, S.M.; Woerner, A.C.; Pinkert, S.; Hecht, M.H.; Tartaglia, G.G.; Vendruscolo, M.; Hayer-Hartl, M.; Hartl, F.U.; Vabulas, R.M. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 2011, 144, 67–78.
63. Tsigelny, I.F.; Bar-On, P.; Sharikov, Y.; Crews, L.; Hashimoto, M.; Miller, M.A.; Keller, S.H.; Platoshyn, O.; Yuan, J.X.-J.; Masliah, E. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J. 2007, 274, 1862–1877.
64. Tsigelny, I.F.; Sharikov, Y.; Wrasidlo, W.; Gonzalez, T.; Desplats, P.A.; Spencer, B.; Masliah, E. Role of alpha-synuclein penetration into the membrane in the mechanisms of oligomer pore formation. FEBS J. 2012, 279, 1000–1013.
65. Butterfield, S.M.; Lashuel, H.A. Amyloidogenic protein-membrane interactions: Mechanistic insight from model systems. Angew. Chem. Int. Ed. Engl. 2010, 49, 5628–5654.
66. Schmidt, F.; Levin, J.; Kamp, F.; Kretzschmar, H.; Giese, A.; Bötzel, K. Single-channel electrophysiology reveals a distinct and uniform pore complex formed by α-synuclein oligomers in lipid membranes. PLOS ONE 2012, 7, e42545.
67. Yoshiike, Y.; Kayed, R.; Milton, S.C.; Takashima, A.; Glabe, C.G. Pore-forming proteins share structural and functional homology with amyloid oligomers. Neuromol. Med. 2007, 9, 270–275.
68. Kayed, R.; Sokolov, Y.; Edmonds, B.; McIntire, T.M.; Milton, S.C.; Hall, J.E.; Glabe, C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 2004, 279, 46363–46366.
69. Sokolov, Y.; Kozak, J.A.; Kayed, R.; Chanturiya, A.; Glabe, C.; Hall, J.E. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J. Gen. Physiol. 2006, 128, 637–647.
70. Capone, R.; Quiroz, F.G.; Prangkio, P.; Saluja, I.; Anna, M.; Bautista, M.R.; Turner, R.S.; Yang, J.; Mayer, M. Amyloid-β-induced ion flux in artificial lipid bilayers and neuronal cells: Resolving a controversy. Neurotox. Res. 2009, 16, 1–13.
71. Zijlstra, N.; Subramaniam, V. α-Synuclein oligomers: An amyloid pore? Insights into mechanisms of α-synuclein oligomer-lipid interactions. Mol. Neurobiol. 2013, 47, 613–621.
72. Stöckl, M.; Claessens, M.M.A.E.; Subramaniam, V. Kinetic measurements give new insights into lipid membrane permeabilization by α-synuclein oligomers. Mol. Biosyst. 2012, 8, 338–345.
73. Nakamura, K. α-Synuclein and mitochondria: Partners in crime? Neurotherapeutics 2013, 10, 391–399.
74. Devi, L.; Raghavendran, V.; Prabhu, B.M.; Avadhani, N.G.; Anandatheerthavarada, H.K. Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283, 9089–9100.
75. Sarafian, T.A.; Ryan, C.M.; Souda, P.; Masliah, E.; Kar, U.K.; Vinters, H.V.; Mathern, G.W.; Faull, K.F.; Whitelegge, J.P.; Watson, J.B. Impairment of mitochondria in adult mouse brainoverexpressing predominantly full-length, N-terminally acetylated human α-synuclein. PLOS ONE 2013, 8, e63557.
76. Luth, E.S.; Stavrovskaya, I.G.; Bartels, T.; Kristal, B.S.; Selkoe, D.J. Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J. Biol. Chem. 2014, 289, 21490–21507.
77. Esteves, A.R.; Gozes, I.; Cardoso, S.M. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson’s disease. Biochim. Biophys. Acta 2014, 1842, 7–21.
78. Zhang, W.; Wang, T.; Pei, Z.; Miller, D.S.; Wu, X.; Block, M.L.; Wilson, B.; Zhang, W.; Zhou, Y.; Hong, J.-S; et al. Aggregated alpha-synuclein activates microglia: A process leading to disease progression in Parkinson’s disease. FASEB J. 2005, 19, 533–542.
79. Chen, L.; Jin, J.; Davis, J.; Zhou, Y.; Wang, Y.; Liu, J.; Lockhart, P.J.; Zhang, J. Oligomeric alpha-synuclein inhibits tubulin polymerization. Biochem. Biophys. Res. Commun. 2007, 356, 548–553.
80. Prots, I.; Veber, V.; Brey, S.; Campioni, S.; Buder, K.; Riek, R.; Böhm, K.J.; Winner, B. α-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J. Biol. Chem. 2013, 288, 21742–21754.
81. Junn, E.; Mouradian, M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 2002, 320, 146–150.
82. Choi, D.-H.; Cristóvão, A.C.; Guhathakurta, S.; Lee, J.; Joh, T.H.; Beal, M.F.; Kim, Y.-S. NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson’s disease. Antioxid. Redox Signal. 2012, 16, 1033–1045.
83. Béraud, D.; Hathaway, H.A.; Trecki, J.; Chasovskikh, S.; Johnson, D.A.; Johnson, J.A.; Federoff, H.J.; Shimoji, M.; Mhyre, T.R.; Maguire-Zeiss, K.A. Microglial activation and antioxidant responses induced by the Parkinson’s disease protein α-synuclein. J. Neuroimmune Pharmacol. 2013, 8, 94–117.
84. Stefanova, N.; Fellner, L.; Reindl, M.; Masliah, E.; Poewe, W.; Wenning, G.K. Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. Am. J. Pathol. 2011, 179, 954–963.
85. Kim, C.; Ho, D.-H.; Suk, J.-E.; You, S.; Michael, S.; Kang, J.; Joong Lee, S.; Masliah, E.; Hwang, D.; Lee, H.-J; et al. Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 2013, doi:10.1038/ncomms2534.
86. Hoozemans, J.J.M.; van Haastert, E.S.; Nijholt, D.A.T.; Rozemuller, A.J.M.; Scheper, W. Activation of the unfolded protein response is an early event in Alzheimer’s and Parkinson’s disease. Neurodegener. Dis. 2012, 10, 212–215.
87. Colla, E.; Jensen, P.H.; Pletnikova, O.; Troncoso, J.C.; Glabe, C.; Lee, M.K. Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J. Neurosci. 2012, 32, 3301–3305.
88. Colla, E.; Coune, P.; Liu, Y.; Pletnikova, O.; Troncoso, J.C.; Schneider, B.L.; Lee, M.K. Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J. Neurosci. 2012, 32, 3306–3320.
89. Su, L.J.; Auluck, P.K.; Outeiro, T.F.; Yeger-Lotem, E.; Kritzer, J.A.; Tardiff, D.F.; Strathearn, K.E.; Liu, F.; Cao, S.; Hamamichi, S; et al. Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson’s disease models. Dis. Model. Mech. 2010, 3, 194–208.
90. Castillo-Carranza, D.L.; Zhang, Y.; Guerrero-Muñoz, M.J.; Kayed, R.; Rincon-Limas, D.E.; Fernandez-Funez, P. Differential activation of the ER stress factor XBP1 by oligomeric assemblies. Neurochem. Res. 2012, 37, 1707–1717.
91. Thayanidhi, N.; Helm, J.R.; Nycz, D.C.; Bentley, M.; Liang, Y.; Hay, J.C. α-Synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol. Biol. Cell 2010, 21, 1850–1863.
92. Cooper, A.A.; Gitler, A.D.; Cashikar, A.; Haynes, C.M.; Kathryn, J.; Bhullar, B.; Liu, K.; Xu, K.; Strathearn, K.E.; Cao, S; et al. α-Synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s models. Science 2006, 313, 324–328.
93. Xilouri, M.; Brekk, O.R.; Stefanis, L. α-Synuclein and protein degradation systems: A reciprocal relationship. Mol. Neurobiol. 2013, 47, 537–551.
94. Emmanouilidou, E.; Stefanis, L.; Vekrellis, K. Cell-produced α-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging 2010, 31, 953–968.
95. Snyder, H.; Mensah, K.; Theisler, C.; Lee, J.; Matouschek, A.; Wolozin, B. Aggregated and monomeric alpha-synuclein bind to the S6’ proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 2003, 278, 11753–11759.
96. Xilouri, M.; Vogiatzi, T.; Vekrellis, K.; Park, D.; Stefanis, L. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLOS ONE 2009, 4, e5515.
97. Cuervo, A.M.; Stefanis, L.; Fredenburg, R.; Lansbury, P.T.; Sulzer, D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305, 1292–1295.
98. Martinez-vicente, M.; Talloczy, Z.; Kaushik, S.; Massey, A.C.; Mazzulli, J.; Mosharov, E.V.; Hodara, R.; Fredenburg, R.; Wu, D.; Follenzi, A.; et al. Dopamine-modified α-synuclein blocks chaperone-mediated autophagy. J. Clin. Investig. 2008, 118, 777–788.
99. Celej, M.S.; Sarroukh, R.; Goormaghtigh, E.; Fidelio, G.D.; Ruysschaert, J.-M.; Raussens, V. Toxic prefibrillar α-synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure. Biochem. J. 2012, 443, 719–726.
100. Pieri, L.; Madiona, K.; Bousset, L.; Melki, R. Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys. J. 2012, 102, 2894–2905.
101. Desplats, P.; Lee, H.; Bae, E.; Patrick, C.; Rockenstein, E.; Crews, L.; Spencer, B.; Masliah, E; Lee, S. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. PNAS 2009, 106, 13010–13015.
102. Hansen, C.; Angot, E.; Bergström, A.; Steiner, J.A.; Pieri, L.; Paul, G.; Outeiro, T.F.; Melki, R.; Kallunki, P.; Fog, K. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Investig. 2011, 121, 715–725.
103. Volpicelli-Daley, L.A.; Luk, K.C.; Patel, T.P.; Tanik, S.A.; Dawn, M.; Stieber, A.; Meany, D.F; Trojanowski, J.Q.; Lee, V.M. Exogenous α-synuclein fibrils induce Lewy Body pathology leading to synaptic dysfunction and neuron death. Neuron 2012, 72, 57–71.
104. Tanik, S.A.; Schultheiss, C.E.; Volpicelli-Daley, L.A.; Brunden, K.R.; Lee, V.M.Y. Lewy body-like α-synuclein aggregates resist degradation and impair macroautophagy. J. Biol. Chem. 2013, 288, 15194–15210.
105. Jan, A.; Adolfsson, O.; Allaman, I.; Buccarello, A.-L.; Magistretti, P.J.; Pfeifer, A.; Muhs, A.; Lashuel, H.A. Abeta42 neurotoxicity is mediated by ongoing nucleated polymerization process rather than by discrete Abeta42 species. J. Biol. Chem. 2011, 286, 8585–8596.
106. Wan, O.W.; Chung, K.K.K. The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson’s disease. PLOS ONE 2012, 7, e38545.
107. Cherny, R.A.; Culvenor, J.G.; Bottomley, S.P.; Masters, C.L. Dopamine promotes α-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 2005, 19, 1377–1379.
108. Sparr, E.; Engel, M.F.M.; Sakharov, D.V.; Sprong, M.; Jacobs, J.; de Kruijff, B.; Höppener, J.W.M.; Killian, J.A. Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. FEBS Lett. 2004, 577, 117–120.
109. Gai, W.; Yuan, H.; Li, X.; Power, J.; Blumbergs, P.; Jensen, P. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp. Neurol. 2000, 166, 324–333.
110. Reynolds, N.P.; Soragni, A.; Rabe, M.; Verdes, D.; Liverani, E.; Handschin, S.; Riek, R.; Seeger, S. Mechanism of membrane interaction and disruption by α-synuclein. J. Am. Chem. Soc. 2011, 133, 19366–19375.
111. Lee, J.-H.; Hong, C.-S.; Lee, S.; Yang, J.-E.; Park, Y.I.; Lee, D.; Hyeon, T.; Jung, S.; Paik, S.R. Radiating amyloid fibril formation on the surface of lipid membranes through unit-assembly of oligomeric species of α-synuclein. PLOS ONE 2012, 7, e47580.
112. Chaudhary, H.; Stefanovic, A.N.D.; Subramaniam, V.; Claessens, M.M.A.E. Membrane interactions and fibrillization of α-synuclein play an essential role in membrane disruption. FEBS Lett. 2014, 588, 4457–4463.
113. Plotegher, N.; Greggio, E.; Bisaglia, M.; Bubacco, L. Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicity. Q. Rev. Biophys. 2014, 47, 1–48.
114. Emmanouilidou, E.; Melachroinou, K.; Roumeliotis, T.; Garbis, S.D.; Ntzouni, M.; Margaritis, L.H.; Stefanis, L.; Vekrellis, K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 2010, 30, 6838–6851.
115. Winner, B.; Jappelli, R.; Maji, S.K.; Desplats, P.A.; Boyer, L.; Aigner, S. In vivo demonstration that α-synuclein oligomers are toxic. PNAS 2011, 108, 4194–4199.
116. Rockenstein, E.; Nuber, S.; Overk, C.R.; Ubhi, K.; Mante, M.; Patrick, C.; Adame, A.; Trejo-Morales, M.; Gerez, J.; Picotti, P; et al. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain 2014, 137, 1496–1513.
117. Karpinar, D.P.; Balija, M.B.G.; Kügler, S.; Opazo, F.; Rezaei-Ghaleh, N.; Wender, N.; Kim, H.-Y.; Taschenberger, G.; Falkenburger, B.H.; Heise, H; et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson’s disease models. EMBO J. 2009, 28, 3256–3268.
118. Taschenberger, G.; Garrido, M.; Tereshchenko, Y.; Bähr, M.; Zweckstetter, M.; Kügler, S. Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons. Acta Neuropathol. 2012, 123, 671–683.
119. Ardah, M.T.; Paleologou, K.E.; Lv, G.; Abul Khair, S.B.; Kazim, A.S.; Minhas, S.T.; Al-Tel, T.H.; Al-Hayani, A.A.; Haque, M.E.; Eliezer, D; et al. Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity. Front. Aging Neurosci. 2014, doi:10.3389/fnagi.2014.00197.
120. Bieschke, J.; Russ, J.; Friedrich, R.P.; Ehrnhoefer, D.E.; Wobst, H.; Neugebauer, K.; Wanker, E.E. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci. USA 2010, 107, 7710–7715.
121. Li, Q.; Gillardon, F.; Hengerer, B.; Berlinicke, C. Baicalein reduces E46K α-synuclein aggregation in vitro and protects cells against E46K α-synuclein toxicity in cell models of familiar Parkinsonism. J. Neurochem. 2011, 114, 419–429